

**Edwin H. Kim**

3004 Mary Ellen Jones Bldg  
116 Manning Dr, CB 8035  
Chapel Hill, NC 27599

**Education**

- 7/2008 – 6/2011 **Duke University School of Medicine, Durham, NC**  
Fellowship: Allergy & Immunology
- 7/2005 – 6/2008 **Duke University School of Medicine, Durham, NC**  
Residency: Pediatrics
- 8/2001 – 6/2005 **UMDNJ-Robert Wood Johnson Medical School, Piscataway Township, NJ**  
MD
- 8/1999 – 6/2001 **Harvard School of Public Health, Boston, MA**  
MS, Health Policy & Management
- 8/1992 – 6/1996 **Massachusetts Institute of Technology, Boston, MA**  
BS, Biology

**Professional Experience – Employment History**

- 7/2021 – present **Associate Professor and Division Chief**  
**University of North Carolina School of Medicine, Department of Pediatrics,**  
Division of Pediatric Allergy and Immunology, *Chapel Hill, NC*
- 11/2019 – 7/2021 **Associate Professor**  
**University of North Carolina School of Medicine, Department of Medicine,**  
Division of Allergy, Immunology and Rheumatology, *Chapel Hill, NC*
- 9/2011 – 10/2019 **Assistant Professor**  
**University of North Carolina School of Medicine, Department of Medicine,**  
Division of Rheumatology, Allergy & Immunology, *Chapel Hill, NC*
- 7/2017 – 6/2021 **Medical Director**  
**University of North Carolina Allergy and Immunology Clinic, Chapel Hill, NC**
- 10/2015 – present **Director**  
**University of North Carolina Food Allergy Initiative Research Group, Chapel Hill,**  
*NC*
- 9/2015 – present **Program Director**  
7/2014 – 8/2015 **Associate Program Director**  
**University of North Carolina Allergy and Immunology Fellowship Training**  
**Program, Chapel Hill, NC**
- 11/2000 – 6/2001 **Intern**  
**The Women’s Care Network, Boston, MA**  
e-health marketplace analysis for development of a web-based physician/patient

interface

6/2000 – 8/2000

**Intern**

**Institute for Medical Quality, San Francisco, CA**

Assessment of California's third-party external review program for denials of medical reimbursement

10/1997 – 1/1999

**Research Technician**

**Dana Farber Cancer Institute, Boston, MA**

Development of a non-radioactive screen for mutations in the BRCA genes using heteroduplex PCR

6/1995 – 5/1997

**Research Technician**

**MIT Department of Biology, Boston, MA**

Investigation of the early development of the immune system in zebrafish

**Certifications/ Licensure**

2011 – present

**American Board of Allergy and Immunology, #5933**

2009 – present

**North Carolina Medical Board Full License, #2008-00846**

2010 – 2015

**American Board of Pediatrics, #97828**

**Honors and Awards**

**Teaching**

2006 – 2007

Intensive Care Nursery Outstanding Junior Resident Award, Duke Medical Center

2005 – 2006

Exceptional Dedication to Medical Student Training Award, Duke Medical Center

**Clinical**

2011 – present

"High 5" (3 written patient commendations), Patient Relations, UNCHealth Care

2005 – 2011

"Service Champion" (8 written patient commendations), Patient-Visitor Relations, Duke Medical Center

**Bibliography and Products of Scholarship**

**Books/Chapters**

L Yang, **EH Kim**. Chapter 19: Emerging Food Allergy Therapies. *Pediatric Food Allergy: A Clinical Guide*. R. Gupta (editor). 2018; 261-270. doi.org/10.1007/978-3-030-33292-1\_19

**EH Kim**, AW Burks. Chapter 18: Food Allergies. *Patterson's Allergic Diseases 8th edition*. L. Grammer & P Greenberger (editors). 2018; 401-421.

**Refereed Papers/Articles**

SM Jones, **EH Kim**, KC Nadeau, A Nowak-Wegrzyn, RA Wood, HA Sampson, AM Scurlock, S Chinthrajah, J Wang, RD Pesek, SB Sindher, M Kulis, J Johnson, K Spain, DC Babineau, H Chin, J Laurienzo-Panza, R Yan, D Larson, T Qin, E Wambre, J Calise, D Whitehouse, ML Sever, S Sanda, M Plaut, LM Wheatley, AW Burks. Efficacy and Safety of Oral Immunotherapy in a Randomized, Placebo-Controlled Study of 1-3-Year Old Children with Peanut Allergy: Findings from the Immune Tolerance Network IMPACT Trial. *Lancet*. 2022; 399(10322):359-371. doi.org/10.1016/S0140-6736(21)02390-4

RS Chinthrajah, SM Jones, **EH Kim**, SH Sicherer, W Shreffler, BJ Lanser, N Atri, DC Babineau, DC Adelman, A Iqbal, SL Limb, AK Rudman-Spergel, A Togias, RA Wood. Updating the CoFAR Grading Scale for Systemic Allergic Reactions in Food Allergy. *J Allergy Clin Immunology*. 2022; doi.org/10.1016/j.jaci.2021.12.789

N Liao, R Scherzer, **EH Kim**. Effective Methods of Clinical Education. *Annals Allergy Clin Immunol*. 2021; doi.org/10.1016/j.anai.2021.11.021

MC Berin, C Agashe, AW Burks, D Chiang, WF Davidson, P Dawson, A Grishin, AK Henning, SM Jones, **EH Kim**, DYM Leung, M Masilamani, AM Scurlock, SH Sicherer, RA Wood, HA Sampson. Allergen-specific T cells and clinical features of food allergy: Lessons from CoFAR immunotherapy cohorts. *J Allergy Clin Immunol*. 2021; doi: 10.1016/j.jaci.2021.09.029

JA Pongratic, R Gagnon, G Sussman, D Siri, RC Oriel, T Brown-Whitehorn, TD Green, DE Campbell, S Anvari, WE Berger, JA Bird, ES Chan, A Cheema, S Chinthrajah, H Chong, PJ Dowling, SM Fineman, DM Fleischer, E Gonzalez-Reyes, **EH Kim**, BJ Lanser, A MacGinnitie, H Mehta, D Petroni, N Rupp, LC Schneider, AM Scurlock, LD Sher, WG Shreffler, SB Sindher, A Stillerman, R Wood, WH Yang, T Bois, HA Sampson, P Begin. Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: REALISE Randomized Clinical Trial Results. *J Allergy Clin Immunol Pract*. 2021; doi.org/10.1016/j.jaip.2021.11.017

A Hung, JM Gonzalez, J Yang, S Hass, **EH Kim**, FR Johnson. Heterogeneity in Parent Preferences for Peanut Desensitization Therapy. *J Allergy Clin Immunol Pract*. 2021; doi.org/10.1016/j.jaip.2021.04.058

J MacDougall, AW Burks, **EH Kim**. Novel Insights into Immunotherapy Approaches for Food Allergy. *Immunotargets Ther*. 2021; doi.org/10.2147/ITT.S266257

SM Barshow, MD Kulis, AW Burks, **EH Kim**. Mechanisms of Oral Immunotherapy. *Clin Exp Allergy*. 2021; doi.org/10.1111/cea.13824

A Penumarti, N Szczepanski, J Kesselring, E Gabel, R Sheth, J Berglund, **EH Kim**, AW Burks, MD Kulis. Irradiated Tree Nut Flours for Use in Oral Immunotherapy. *J Allergy Clin Immunol Pract*. 2021; 9:321-7. doi.org/10.1016/j.jaip.2020.11.008

L Herlihy, **EH Kim**, AW Burks, H Barber, Q Cook, L Yang, DK Hamilton, BP Vickery. Five-year Follow-up of Early Intervention Peanut Oral Immunotherapy. *J Allergy Clin Immunol Pract*. 2021; 9:514-7. doi.org/10.1016/j.jaip.2020.07.009

AM Scurlock, AW Burks, SH Sicherer, DYM Leung, **EH Kim**, AK Henning, P Dawson, RW Lindblad, MC Berin, CB Cho, WF Davidson, M Plaut, HA Sampson, RA Wood, SM Jones. Epicutaneous Immunotherapy for Treatment of Peanut Allergy: Follow-up from the Consortium for Food Allergy Research. *J Allergy Clin Immunol*. 2020; doi.org/10.1016/j.jaci.2020.11.027

**EH Kim**, TT Perry, RA Wood, DYM Leung, MC Berin, AW Burks, CB Cho, SM Jones, A Scurlock, SH Sicherer, AK Henning, P Dawson, RW Lindblad, M Plaut, HA Sampson. Induction of Sustained

Unresponsiveness After Egg Oral Immunotherapy Compared to Baked Egg Therapy in Egg-allergic Children. *J Allergy Clin Immunol*. 2020; 146:851-62. doi.org/10.1016/j.jaci.2020.05.040

SA Schworer, **EH Kim**. Sublingual Immunotherapy for Food Allergy and its Future Directions. *Immunotherapy*. 2020; 12:921-31. doi.org/10.2217/imt-2020-0123

Q Cook, L Yang, A Hamad, H Barber, L Herlihy, AW Burks, **EH Kim**. Dosing, Safety, and Quality of Life After Peanut Immunotherapy Trials – a Long-term Follow Up Study. *J Allergy Clin Immunol Pract*. 2020; 8:2805-7. doi.org/10.1016/j.jaip.2020.04.021

DM Fleischer, WG Shreffler, DE Campbell, TD Green, S Anvari, A Assa'ad, P Bégin, K Beyer, JA Bird, T Brown-Whitehorn, A Byrne, ES Chan, A Cheema, S Chinthrajah, H Chong, CM Davis, LS Ford, R Gagnon, M Greenhawt, JO Hourihane, SM Jones, **EH Kim**, L Lange, BJ Lanser, S Leonard, V Mahler, A Maronna, A Nowak-Wegrzyn, RC Oriel, M O'Sullivan, D Petroni, JA Pongratic, SL Prescott, LC Schneider, P Smith, D Staab, G Sussman, R Wood, WH Yang, R Lambert, A Peillon, T Bois, HA Sampson. Long-Term, Open-Label Extension Study of the Efficacy and Safety of Epicutaneous Immunotherapy for Peanut Allergy in Children: PEOPLE 3-Year Results. *J Allergy Clin Immunol*. 2020; 146:863-74. doi.org/10.1016/j.jaci.2020.06.028

DM Fleischer, JM Spergel, **EH Kim**, DE Campbell, TD Green, KJ Bee, RLambert, T Ocheltree, HA. Sampson. Evaluation of Daily Patch Application Duration for Epicutaneous Immunotherapy for Peanut Allergy. *Allergy Asthma Proc*. 2020; 41:278–284, 2020; doi.org/10.2500/aap.2020.41.200045

M Greenhawt, **EH Kim**, DE Campbell, TD Green, R Lambert, DM Fleischer. Improvements in Eliciting Dose Across Baseline Sensitivities Following 12 Months of Epicutaneous Immunotherapy (EPIT) in Peanut-Allergic Children Aged 4 to 11 Years. *J Allergy Clin Immunol Pract*, 2020; 8:3219-21. doi.org/10.1016/j.anai.2020.01.030

M Greenhawt, M Shaker, T Winders, D Buckstein, R Davis, DM Fleischer, **EH Kim**, E Chan, D Stukus, D Matlock. Development and Acceptability of a Shared Decision-Making Tool for Commercial Peanut Allergy Therapies. *Ann Allergy Clin Immunol*. 2020; 125:90-6. doi.org/10.1016/j.anai.2020.01.030

**EH Kim**, AW Burks. Food Allergy Immunotherapy: OIT and EPIT. *Allergy*. 2020; 75:1337-46. doi.org/10.1111/all.14220

**EH Kim**, C Patel, AW Burks. Immunotherapy Approaches for Peanut Allergy. *Expert Review of Clinical Immunology*. 2020; 16(2):167-74. doi.org/10.1080/1744666X.2019.1708192

**EH Kim**, SM Jones, AW Burks, RA Wood, SH Sicherer, DYM Leung, AK Henning, RW Lindblad, P Dawson, C Keet, AM Scurlock, M Plaut, HA Sampson. A 5-year Summary of Real-life Dietary Egg Consumption after Completion of a 4-year Egg OIT Protocol. *J Allergy Clin Immunol*. 2020; 145:1292-5. doi.org/10.1016/j.jaci.2019.11.045

**EH Kim**, L Yang, P Ye, R Guo, Q Li, MD Kulis, AW Burks. Long-Term Sublingual Immunotherapy for Peanut Allergy in Children: Clinical and Immunologic Evidence of Desensitization. *J Allergy Clin Immunol*. 2019; 144(5):1320-1326.e1. doi.org/10.1016/j.jaci.2019.07.030.

BC Remington, T Krone, **EH Kim**, JA Bird, TD Green, G Lack, DM Fleischer, SJ Koppelman. Estimated Risk Reduction to Packaged Food Reactions by Epicutaneous Immunotherapy (EPIT) for Peanut Allergy. *Ann Allergy Asthma Immunol*. 2019; 123(5):488-493.e2. doi.org/10.1016/j.anaai.2019.08.007.

DM Fleischer, M Greenhawt, G Sussman, P Bégin, A Nowak-Wegrzyn, D Petroni, K Beyer, T Brown-Whitehorn, J Hebert, JO Hourihane, DE Campbell, S Leonard, RS Chinthrajah, JA Pongratic, SM Jones, L Lange, H Chong, TD Green, R Wood, A Cheema, SL Prescott, P Smith, W Yang, ES Chan, A Byrne, A Assa'ad, JA Bird, **EH Kim**, L Schneider, CM Davis, BJ Lanser, R Lambert, W Shreffler. Effect of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy: The PEPITES Randomized Clinical Trial. *JAMA*. 2019; 321:946-55. doi.org/10.1001/jama.2019.1113

Q Cook, **E Kim**. Update on Peanut Allergy: Prevention and Immunotherapy. *Allergy Asthma Proc*. 2019; 40(1):14-20. doi.org/10.2500/aap.2019.40.4190

P Gamage, C McMahan; M Chaudhari, **E Kim**, M Kosorok. A Proportional Hazards Model for Interval-censored Data Subject to Instantaneous Failures. *Lifetime Data Anal*. 2020; 26(1):158-182

M Kulis, X Yue, R Guo, H Zhang, K Orgel, P Ye, Q Li, Y Liu, **E Kim**, A Burks, B Vickery. High and Low Dose Oral Immunotherapy Similarly Suppress Pro-Allergic Cytokines and Basophil Activation in Young Children. *Clin Exp Allergy*. 2019; 49(2):180-189

BP Vickery, A Vereda, TB Casale, K Beyer, G du Toit, JO Hourihane, SM Jones, WG Shreffler, A Marcantonio, R Zawadzki, L Sher, WW Carr, S Fineman, L Greos, R Rachid, MD Ibáñez, S Tilles, AH Assa'ad, C Nilsson, N Rupp, MJ Welch, G Sussman, S Chinthrajah, K Blumchen, E Sher, JM Spergel, FE Leickly, S Zielen, J Wang, GM Sanders, RA Wood, A Cheema, C Bindslev-Jensen, S Leonard, R Kachru, DT Johnston, FC Hampel, **EH Kim**, A Anagnostou, JA Pongratic, M Ben-Shoshan, HP Sharma, A Stillerman, HH Windom, WH Yang, A Muraro, JM Zubeldia, V Sharma, MJ Dorsey, HJ Chong, J Ohayon, JA Bird, TF Carr, D Siri, M Fernández-Rivas, DK Jeong, DM Fleischer, JA Lieberman, AEJ Dubois, M Tsoumani, CE Ciaccio, JM Portnoy, LE Mansfield, SB Fritz, BJ Lanser, J Matz, HNG Oude Elberink, P Varshney, SG Dilly, DC Adelman, AW Burks. AR101 Oral Immunotherapy for Peanut Allergy. *N Eng J Med*. 2018; 379:1991-2001. doi.org/10.1056/NEJMoa1812856

M Chaudhari, **EH Kim**, PW Gamage, CS McMahan, MR Kosorok. Study Design with Staggered Sampling Times for Evaluating Sustained Unresponsiveness to Peanut Sublingual Immunotherapy. *Stat Med*. 2018; 37:3944–3958

WG Shreffler, JL Baumert, BC Remington, SJ Koppelman, C Dinakar, DM Fleischer, **E Kim**, SA Tilles, JM Spergel. The Importance of Reducing risk in Peanut Allergy: Current and Future Therapies. *Ann Allergy Asthma Immunol*. 2018; 120:124–127

JA Bird, J Spergel, S Jones, R Rachid, A Assa'ad, J Wang, SA Leonard, S Laubach, **EH Kim**, BP Vickery, BP Davis, J Heimall, A Cianferoni, AJ MacGinnitie, E Crestani, W Burks. Efficacy and Safety of AR101 in Oral Immunotherapy for Peanut Allergy: Results of ARC001, a Randomized, Double-blind, Placebo-controlled Phase-2 Clinical Trial. *J Allergy Clin Immunol In Pract*. 2018; 6:476-485

A Hamad, OI Iweala, C Henderson, S Madan, GA Stouffer 3rd, SP Commins, **EH Kim**. Recurrent

Anaphylaxis During Cardiac Catheterization Due to Ethylene Oxide. *J Allergy Clin Immunol Pract.* 2018; 6(6):2148-50

HX Chen, R Blasiak, **E Kim**, R Padilla, DA Culton. Triggers of Oral Lichen Planus Flares and the Potential Role of Trigger Avoidance in Disease Management. *Oral Surg Oral Med Oral Pathol Oral Radiol.* 2017; 124:248-252

BP Vickery, JP Berglund, CM Burk, JP Fine, **EH Kim**, JI Kim, CA Keet, M Kulis, KG Orgel, R Guo, PH Steele, YV Virkud, P Ye, BL Wright, RA Wood, AW Burks. Early Oral Immunotherapy in Peanut-allergic Preschool Children is Safe and Highly Effective. *J Allergy Clin Immunol.* 2017; 139(1):173-181

A Hamad, **EH Kim**. Early Introduction of Allergenic Foods is Safe and May Be Beneficial. *J Allergy Clin Immunol In Pract.* 2016; 5(2):531-532

C Burk, M Kulis, N Leung, **EH Kim**, AW Burks, BP Vickery. Utility of Component Analyses in Subjects Undergoing Sublingual Immunotherapy for Peanut Allergy. *Clin Exp Allergy.* 2016; 46(2):347-353

SJ Chin, BP Vickery, MD Kulis, **EH Kim**, P Varshney, P Steele, J Kamilaris, AM Hiegel, SK Carlisle, PB Smith, AM Scurlock, SM Jones, AW Burks. Sublingual Versus Oral Immunotherapy for Peanut-allergic Children: A Retrospective Comparison. *J Allergy Clin Immunol.* 2013; 132(2):476-478

MD Kulis, K Saba, **EH Kim**, JA Bird, N Kamilaris, BP Vickery, H Staats, AW Burks. Increased Peanut-specific IgA in Saliva Correlates with Food Challenge Outcomes Following Peanut Sublingual Immunotherapy. *J Allergy Clin Immunol.* 2012; 129(4):1159-1162

**EH Kim**, JA Bird, MD Kulis, S Laubach, L Pons, WG Shreffler, PH Steele, J Kamilaris, BP Vickery, AW Burks. Sublingual Immunotherapy for Peanut Allergy: Clinical and Immunologic Evidence of Desensitization. *J Allergy Clin Immunol.* 2011; 127(3):640-646

TD Green, VS LaBelle, PH Steele, **EH Kim**, LA Lee, VS Mankad, LW Williams, KJ Anstrom, AW Burks. Clinical Characteristics of Peanut-allergic Children: Recent Changes. *Pediatrics.* 2007; 120(6):1304-1310

N Danilova, VS Hohman, **EH Kim**, LA Steiner. Immunoglobulin Variable-region Diversity in the Zebrafish. *Immunogenetics.* 2000; 52:81-91

### **Refereed Published Abstracts**

**EH Kim**, JA Bird, L Herlihy, A Arneson, D Hamilton, P Ye, MD Kulis, AW Burks. Safety and efficacy of peanut sublingual immunotherapy in toddler-aged peanut-allergic children. *J Allergy Clin Immunol* 2021; 147(2) Supp: AB235. (virtual late breaking oral abstract presenter)

MD Kulis, J Smeekens, **EH Kim**, V Zarnitsyn, S Patel. Peanut protein-loaded microneedle patches are immunogenic and distinct from subcutaneous delivery. *J Allergy Clin Immunol* 2021; 147(2) Supp: AB237. (virtual late breaking oral abstract)

S Barshow, B Hulburt, J McBride, S Maleki, P Ye, Q Li, AW Burks, MD Kulis, **EH Kim**. Biomarkers for Desensitization in Patients Undergoing Sublingual Immunotherapy for Peanut Allergy. *J Allergy Clin*

*Immunol* 2021; 147(2) Supp: AB110. (virtual poster)

O Francis, MD Kulis, P Ye, **EH Kim**. Effect on age on clinical and immunologic efficacy of peanut sublingual immunotherapy. *J Allergy Clin Immunol* 2021; 147(2) Supp: AB164. (virtual poster)

EGA Iglesia, H Smith, **EH Kim**, ML Hernandez. Clinical Documentation of Peanut Allergy Prevention in an Academic Learning Health System. *J Allergy Clin Immunol* 2021; 147(2) Supp: AB170. (virtual poster)

J Macdougall, **EH Kim**. Long-Term Safety Behaviors and Receipt of Specialized Allergy Care Following Oral or Sublingual Immunotherapy. *J Allergy Clin Immunol* 2020; 145(2) Supp: AB84. (virtual oral abstract)

SM Jones, **EH Kim**. K Nadeau, A Nowak-Wegrzyn, RA Wood, HA Sampson, AM Scurlock, S Chinthrajah, J Johnson, K Spain, J Laurienzo, D Larson, M Plaut, T Qin, S Sanda, M Sever, L Wheatley, D Whitehouse, R Yan, AW Burks. Tolerance Development Following Oral Immunotherapy (OIT) in 1-3 Year Old Children with Peanut Allergy: Findings from the Immune Tolerance Network (ITN) IMPACT TRIAL. *J Allergy Clin Immunol* 2020; 145(2) Supp: AB338. (virtual late breaking oral abstract)

EGA Iglesia, C Patel, AW Burks, **EH Kim**. Characteristics and Rates of In-Home, Dose-Related Adverse Events During Peanut Sublingual Immunotherapy. *J Allergy Clin Immunol* 2020; 145(2) Supp: AB141. (virtual poster)

**EH Kim**, SM Jones, AW Burks, RA Wood, SH Sicherer, DYM Leung, AK Henning, RW Lindblad, P Dawson, C Keet, AM Scurlock, HA Sampson. A 5-year Summary of Real-life Dietary Egg Consumption after Completion of a 4-year Egg OIT Protocol. *J Allergy Clin Immunol* 2019; 143(2) Supp: AB82. (oral abstract presenter)

W Carr, BP Vickery, R Zawadzki, NM Griffin, DC Adelman, A Ratnayake, **EH Kim**. Estimating the Probability of Tolerating Each Challenge Dose of Peanut Protein at Exit Double-Blind, Placebo-Controlled Food Challenge: Results from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial (PALISADE) of AR101. *J Allergy Clin Immunol* 2019; 143(2) Supp: AB262. (poster presenter)

Q Cook, L Yang, A Hamad, H Barber, L Herlihy, AW Burks, **EH Kim** Dosing and Safety of Peanut Food Equivalents After Immunotherapy Trials. *J Allergy Clin Immunol* 2019; 143(2) Supp: AB244. (poster)

L Yang, Q Cook, A Hamad, H Barber, L Herlihy, AW Burks, **EH Kim**. Back to Life, Back to Reality – What Happens after Peanut Immunotherapy? A Long-Term Follow-up Study on Perceptions of Safety and Lifestyle. *J Allergy Clin Immunol* 2019; 143(2) Supp: AB246. (poster)

L Herlihy, **EH Kim**, A Hamad, Q Cook, DK Hamilton, H Barber, AW Burks, BP Vickery. Five Year Follow-Up of Early Intervention Peanut OIT Showed Characteristics of Sustained and Prolonged Clinical Benefit. *J Allergy Clin Immunol* 2019; 143(2) Supp: AB264. (poster)

A Penumarti, N Szczepanski, J Kesselring, E Gabel, R Sheth, JP Berglund, **EH Kim**, AW Burks, MD Kulis. Irradiated Almond Flour Meets Established Criteria for use in Oral Immunotherapy. *J Allergy Clin Immunol* 2019; 143(2) Supp: AB244. (poster)

D Fleischer, TF Brown-Whitehorn, SM Jones, **EH Kim**, KC Nadeau, J Wang, RA Wood, AH Nowak-Wegrzyn, A Jaffrelot, TD Green, AW Burks. Epicutaneous Immunotherapy (EPIT) for Peanut Allergy in Young Children. *J Allergy Clin Immunol* 2019; 143(2) Supp: AB247. (poster)

HA Sampson, DYM Leung, SM Jones, SH Sicherer, AW Burks, A Henning, RW Lindblad, P Dawson, TT Perry, **EH Kim**, RA Wood. Egg Oral Immunotherapy (OIT) Induces More Rapid Desensitization and Sustained Unresponsiveness (SU) in Egg-Allergic, Baked-egg Tolerant Children than the Addition of Daily Baked-egg Products. *J Allergy Clin Immunol* 2019; 143(2) Supp: AB255. (poster)

AS Larionov, I Stavakaki, **EH Kim**, SH Sicherer, RA Wood, PR Couroux, EG Gonzalez-Reyes, I Hussain, SA Tilles, D Opstelten, A Narkus. Development Of A Subcutaneous Immunotherapy (SCIT) With A Modified Peanut Extract Formulation For The Treatment Of Peanut Allergy. *J Allergy Clin Immunol* 2019; 143(2) Supp: AB243. (poster)

L Herlihy, **EH Kim**, A Hamad, Q Cook, DK Hamilton, H Barber, AW Burks, BP Vickery. Five Year Follow-Up Of Early Intervention Peanut OIT Showed Characteristics of Sustained and Prolonged Clinical Benefit. *J Allergy Clin Immunol* 2019; 143(2) Supp: AB164. (poster)

W Carr, BP Vickery, R Zawadzki, NM Griffin, DC Adelman, **EH Kim**. Estimating the Probability of Tolerating Each Challenge Dose of Peanut Protein at Exit Double-Blind, Placebo-Controlled Food Challenge: Results from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial (PALISADE) of AR101. *J Allergy Clin Immunol* 2019; 143(2) Supp: AB262. (poster)

M Chaudhari, **EH Kim**. Study Design with Staggered Sampling Times for Evaluating Sustained Unresponsiveness to Peanut Sublingual Immunotherapy. *J Allergy Clin Immunol* 2018; 141(2) Supp: AB88. (oral abstract)

A Hamad, **EH Kim**. A Novel Assessment of Sustained Unresponsiveness (SU) after Long-term Sublingual Immunotherapy (SLIT) in Peanut-allergic Children: Results of a 4-year Phase II Clinical Trial. *J Allergy Clin Immunol* 2018; 141(2) Supp: AB200. (featured poster)

A Penumarti, **EH Kim**. Impact of Irradiation on the Protein Content and Microbial Levels of Sesame Seed Flour for Use in Oral Immunotherapy. *J Allergy Clin Immunol* 2018; 141(2) Supp: AB241. (poster)

DK Hamilton, **EH Kim**. Assessing the Validity of an IRB approved REDCap Web-based Clinical Trials Recruitment Registry. *J Allergy Clin Immunol* 2018; 141(2) Supp: AB257. (poster)

Q Cook, **E Kim**. Characteristics of Preschool-Aged Children Currently Enrolled in a Phase II Double Blind Placebo Controlled Study of Peanut Sublingual Immunotherapy. *J Allergy Clin Immunol* 2018; 141 Supp: AB263. (poster)

L Yang, PH Steele, D Hamilton, S Bennick, L Herlihy, E Pitkin, AW Burks, **EH Kim**. Sustained Unresponsiveness After Sublingual Immunotherapy for Peanut-allergic Children. *J Allergy Clin Immunol*. 2017; 139(2) Supp: AB175. (oral abstract)

X Yue, M Kulis, H Zhang, R Guo, K Orgel, **EH Kim**, AW Burks, BP Vickery. Low and High Dose Peanut OIT Similarly Suppress Th2 Cytokine and Basophil Activation Responses. *J Allergy Clin Immunol*. 2017; 139(2) Supp: AB562. (oral abstract, presenter)

A Penumarti, N Szczepanski, J Kesselring, E Gabel, **EH Kim**, AW Burks, M Kulis. Impact of Microwaving on the Protein Content and Microbial Levels of Whole Wheat Flour for Use in Oral Immunotherapy. *J Allergy Clin Immunol*. 2017; 139(2) Supp: AB866. (oral abstract, presenter)

A Hamad, D Hamilton, P Steele, S Bennick, L Herlihy, E Pitkin, **EH Kim**, AW Burks. Sublingual Peanut Immunotherapy: Role of Duration and Dose. *J Allergy Clin Immunol*. 2017; 139(2) Supp: AB61. (poster)

L Herlihy, S Bennick, D Hamilton, E Pitkin, **EH Kim**. Controlled Asthma Not Correlated with Respiratory Symptoms During DBPCFCs (Double-blind, Placebo-controlled Food Challenges) to Peanut in Children. *J Allergy Clin Immunol*. 2017; 139(2) Supp: AB420. (poster)

M Kulis, C Burk, X Yue, H Zhang, R Guo, K Orgel, P Ye, BP Vickery, **EH Kim**, AW Burks. Six-month Course of Peanut OIT Leads to Suppression of Basophil Activation Which Begins to Wane Within Four Weeks After OIT is Stopped. *J Allergy Clin Immunol*. 2017; 139(2) Supp: AB430. (poster)

**EH Kim**, BP Vickery, A Radwan, AW Burks. Immunologic Effects of AR101 During Characterized Oral Desensitization Immunotherapy (CODIT) for Peanut Allergy. *Ann Allergy Asthma Immunol*. 2016; 117(5) Supp: O055. (oral abstract, presenter)

A Fatima, **EH Kim**. Eosinophilic Gastroenteritis in a Study of Sublingual Immunotherapy (SLIT) for Peanut Allergy. *Ann Allergy Asthma Immunol*. 2016; 117(5) Supp: P272. (poster)

P Ye, MD Kulis, RGuo, **EH Kim**, BP Vickery, AW Burks. Sublingual Immunotherapy (SLIT) Regulates the Expression of Transcription Factors and Interleukins in Peanut-Allergic Children. *J Allergy Clin Immunol*. 2016; 137(2) Supp: AB194. (featured poster)

ME Breslin, DK Hamilton, R Guo, P Ye, X Jiang, P Stewart, S Chin, **EH Kim**, AW Burks. Basophil Activation and Peanut-Specific IgE Are Not Predictors of Threshold Dose during a Double-Blind Placebo-Controlled Food Challenge (DBPCFC). *J Allergy Clin Immunol*. 2016; 137(2) Supp: AB125. (poster)

JA Bird, JM Spergel, SM Jones, R Rachid, AH Assa'ad, J Wang, SA Leonard, SS Laubach, **EH Kim**, BP Vickery, B Davis, J Heimall, A Cianferoni, AJ MacGinnitie, E Crestani, RM Elfont, HA Sampson, AW Burks. A Novel Characterized Peanut Allergen Formulation (AR101) for Oral Immunotherapy (OIT) Induces Desensitization in Peanut-allergic Subjects: a Phase 2 Clinical Safety and Efficacy Study. *Allergy*, 2015; 70:110. (oral abstract)

**EH Kim**, PH Steele, MD Kulis, A Beavers, DK Hamilton, R Guo, BP Vickery, AW Burks. Peanut Sublingual Immunotherapy (SLIT) Results in Sustained Unresponsiveness in a Subset of Peanut-allergic Children. *J Allergy Clin Immunol*. 2015; 135(2) Supp: AB155. (oral abstract)

**EH Kim**, SJ Chin, P Steele, J Kamilaris, N Kamilaris, C Burk, M Kulis, BP Vickery, AW Burks. Tolerance

Induction in an Interim Analysis of Peanut Sublingual Immunotherapy. *J Allergy Clin Immunol*. 2013; 131(2) Supp: AB130. (oral abstract, presenter)

**EH Kim**, MD Kulis, BP Vickery, AW Burks. Induction of Regulatory T-cells After Peanut Sublingual Immunotherapy. *J Allergy Clin Immunol*. 2012; 129(2) Supp: AB27. (poster, presenter)

**EH Kim**, JA Bird, MD Kulis, S Laubach, L Pons, WG Shreffler, PH Steele, J Kamilaris, BP Vickery, AW Burks. Evidence of Desensitization in a Study of Sublingual Immunotherapy for Peanut Allergy. *Clin Exp Allergy*. 2011; 41:1823. (oral abstract, presenter)

**EH Kim**, JA Bird, MD Kulis, S Laubach, L Pons, WG Shreffler, PH Steele, J Kamilaris, BP Vickery, AW Burks. Evidence of Desensitization by Sublingual Immunotherapy in Peanut-Allergic Children. *J Allergy Clin Immunol*. 2011; 127(2) Supp: AB72. (oral abstract, presenter)

**EH Kim**, JA Bird, PH Steele, J Kamilaris, AH Edie, BP Vickery, AW Burks. Safety of Peanut Sublingual Immunotherapy (SLIT) in Children with Peanut Allergy. *J Allergy Clin Immunol*. 2010; 125(2) Supp: AB20. (poster, presenter)

### **Unrefereed Publications**

OL Francis, **EH Kim**. Peanut Immunotherapy: Practical Applications. *Curr Treat Options Allergy*. 2021. doi.org/10.1007/s40521-021-00292-0

EGA Iglesia, **EH Kim**. Shorter “Time to Peanut Introduction” Can Prevent Peanut Allergy and Avert False Allergy Screening Results in Infants. *J Allergy Clin Immunol*. 2021. doi.org/10.1016/j.jaci.2021.03.039

HG Smith, **EH Kim**. Increasing Diversity in Peanut Oral Immunotherapy Research and Accessibility. *J Allergy Clin Immunol Pract*. 2021; 9(5):2132-3. doi.org/10.1016/j.jaip.2021.02.010

OL Francis, KY Wang, **EH Kim**, TP Moran. Common Food Allergens and Cross-Reactivity. *J Food Allergy*. 2020; 2(1):17-21. doi.org/10.2500/jfa.2020.2.200020

EGA Iglesia, **EH Kim**. Low-Risk Infants May Still Benefit from Allergenic Food Consumption. *J Allergy Clin Immunol*. 2020; 145(4):1305. doi.org/10.1016/j.jaci.2020.01.016

J Waldron, **EH Kim**. Sublingual and Patch Immunotherapy for Food Allergy. *Immunol Allergy Clin N Am*. 2020; 40(1):135-148. doi.org/10.1016/j.iac.2019.09.008.a

CP Parrish, **EH Kim**, JA Bird. Interventional Therapies for the Treatment of Food Allergy. *Immunol Allergy Clin N Am*. 2018; 38(1):77-88

S Commins, **EH Kim**, K Orgel, M Kulis. Peanut Allergy: New Developments and Clinical Implications. *Curr Allergy Asthma Rep*. 2016; 16:35

**EH Kim**, AW Burks. Immunological basis of Food Allergy (IgE-mediated, Non-IgE-mediated, and tolerance). *Chemical Immunology and Allergy*. RA Wood (editors). 2015; 101:8-16

**EH Kim.** Food Challenge. *Encyclopedia of Medical Immunology – Allergic Diseases*. IR Mackay, NR Rose (editors). 2014.

**EH Kim, AW Burks.** Oral and Sublingual Immunotherapy. *Current Treatment Options in Allergy*. M Worm, L Cox (editors). 2013; doi.org/10.1007/s40521-013-0004-7

**EH Kim, W Burks.** Managing Food Allergy in Childhood. *Curr Opin Pediatr*. 2012; 24:615-20  
**M Land, EH Kim, AW Burks.** Oral desensitization for food hypersensitivity. *Immunol Allergy Clin N Am*. 2011; 31: 267-276

**R Firszt, EH Kim, L McWilliams, E Wu, SR Boden, S Chin.** The Role of Pharmacogenomics in Improving the Management of Asthma – CME exam. *J Allergy Clin Immunol*. 2010; 125: 303-304

## **Teaching Activities**

### **Teaching and Mentorship training activities**

- 5/2014 – present Elected to the UNC **Academy of Educators**
- 1/2019 Selected for inaugural **Making the Case** leadership development program
- 9/2017 – 5/2018 Selected for **Leadership Advanced** leadership development program
- 4/2017 Selected for **Being a Better Faculty Research Mentor (BBFRM)** training program
- 3/2017 – 3/2018 Selected for the **AAAAI Leadership Institute** Course and Mentorship Programs
- 9/2015 – 12/2016 Selected for the **Academic Career Leadership Academy in Medicine (ACCLAIM)** program
- 9/2015 – 6/2016 Selected for the **Passing the Torch: Fostering Medical Humanism through Faculty Role-Models** program
- 9/2013 – 8/2014 Selected for the UNC **Teaching Scholars Program**

### **Fellowship Didactics**

- Weekly case conference preceptor
- Ad-hoc topic-centered journal club preceptor:

### **Teaching roles with Trainees/Students**

- MS1 MTEC 101 Immunology Block, “Hypersensitivity”: Lecturer, 2014 – present
- MS2 Transition course: Small group preceptor, 2015 – 2018
- MS1 Patient Centered Care course: Small group tutor, 2014 – 2017
- UNC Allergy and Immunology Fellowship: Program director, continuity clinic preceptor
- UNC Internal Medicine residency elective – Allergy and Immunology: Faculty supervisor
- UNC Pediatric residency elective – Allergy and Immunology: Faculty supervisor
- MS4 course MEDI523/PEDS440 – Allergy and Immunology (med/peds) elective; advanced clinical selective: Course director
- MS3 course Community Based Longitudinal Care (CBLC) – allergy subspecialty experience: Subspecialty supervisor
- UNC AED premedical society shadowing program: Subspecialty supervisor

### **Grand Rounds Presentations**

- 12/2/2021 Beyond OIT: What are the Options for Peanut Allergy. Rutgers New Jersey Medical School Allergy and Immunology Grand Rounds. Newark, NJ (virtual)

4/7/2021 Update on the Diagnostic Approach to Food Allergy. UNC Otolaryngology Grand Rounds. Chapel Hill, NC. (virtual)

8/27/2020 Oral Immunotherapy: How We Got Here and Where We Go Next. UNC Department of Pediatrics Virtual Grand Rounds. Chapel Hill, NC (virtual)

4/3/2020 Food Immunotherapy. UNC Rheumatology, Allergy and Immunology Virtual Grand Rounds. Chapel Hill, NC. (virtual)

3/21/2019 Immunotherapy for the Treatment of Peanut Allergy. UNC Department of Pathology Grand Rounds. Chapel Hill, NC.

3/20/2019 Immunotherapy for Food Allergy. UNC Otolaryngology Grand Rounds. Chapel Hill, NC.

1/10/2019 Emerging Therapies for Peanut Allergy. New Jersey Medical School Allergy & Immunology Grand Rounds. Newark, NJ.

10/17/2018 Basics of Food allergy. NC AHEC New Hanover Medical Center Internal Medicine Grand Rounds. Wilmington, NC.

3/22/2018 Drug Allergies Affecting the Care of Inpatients. UNC Department of Medicine Grand Rounds. Chapel Hill, NC.

8/31/2017 General Pediatrician as Food Allergist? Review of the LEAP study for Peanut Allergy. UNC Department of Pediatrics Grand Rounds. Chapel Hill, NC.

4/15/2016 Learning Early About Peanut Allergy (LEAP). UNC Rheumatology, Allergy and Immunology Grand Rounds. Chapel Hill, NC.

10/15/2015 Food immunotherapy: Where are we now? Achoo! What's New? Pediatric Allergy Update Conference. Children's Hospital of the King's Daughters. Norfolk VA.

12/17/2014 Nut-free, gluten-free, red meat-free living? Making sense of food allergies. NC AHEC New Hanover Medical Center Internal Medicine Grand Rounds. Wilmington, NC.

5/21/2013 Advances in the diagnosis and treatment of chronic urticaria. NC AHEC, Carolinas Medical Center Internal Medicine Grand Rounds. Charlotte, NC.

8/31/2012 Chronic urticaria and angioedema. UNC Rheumatology, Allergy and Immunology Grand Rounds. Chapel Hill, NC.

4/29/2011 Evidence of Desensitization in a Study of Sublingual Immunotherapy for Peanut Allergy. UNC Rheumatology, Allergy and Immunology Grand Rounds, Chapel Hill, NC.

**Invited Lectures**

- 9/17/2021 Update on Therapies for Food Allergy. 2021 Children's Mercy Kansas City/ACAAI Conferences On-Line Allergy (COLA) conference series.
- 6/11/2021 Mechanisms and Routes of Immunotherapy for Food Allergy. Symposium on Specific Allergy, eSOSA 2021. (virtual)
- 5/22/2021 Food Immunotherapy. North Carolina Asthma, Allergy and Immunology Society 2021 Virtual Annual Meeting. (virtual)
- 2/20/2021 Update on Food Allergy. 2021 American Academy of Allergy, Asthma and Immunology Virtual Annual Meeting – Chrysalis Project Program. (virtual)
- 11/13/2020 FDA-approved Oral Immunotherapy. 2020 American College of Allergy, Asthma and Immunology Annual Scientific Meeting. (virtual)
- 10/2/2020 Update on Food Allergy Research and Treatment. 2020 Children's Mercy Kansas City/ACAAI Conferences On-Line Allergy (COLA) conference series.
- 9/22/2020 Peanut Sublingual Immunotherapy Induction of Clinical Tolerance of Newly Diagnosed Peanut Allergic 12 to 48-Month-Old Children. FARE Contains: Courage® Research Retreat. (virtual)
- 9/20/2020 Peanut Oral Immunotherapy: Practical Considerations. 2020 Southeastern Allergy, Asthma and Immunology Society 2020 Annual Meeting, Gulf Springs, AL. (virtual)
- 9/20/2020 Food Allergy Treatment Options. 2020 Southeastern Allergy, Asthma and Immunology Society 2020 Annual Meeting. Gulf Springs, AL. (virtual)
- 3/13/2020 Peanut OIT from the Research Perspective. 2020 American Academy of Allergy, Asthma and Immunology Annual Scientific Meeting. Philadelphia, PA. (virtual)
- 11/8/2019 Implementing Food Allergy Therapy in Clinical Practice. 2019 American College of Allergy, Asthma and Immunology Annual Scientific Meeting. Houston, TX.
- 11/7/2019 Treatment Updates: What are our Present Options? 2019 American College of Allergy, Asthma and Immunology Annual Scientific Meeting. Houston, TX.
- 9/28/2019 Food Allergy Primer. Chapel Hill Pediatrics: Listen, Learn, & Share. Chapel Hill, NC.
- 9/13/2019 Update on Food Allergy Research. 2019 Children's Mercy Kansas City/ACAAI Conferences On-Line Allergy (COLA) conference series.
- 4/5/2019 Immunotherapy for Food Allergy. UNC Medical Alumni Council spring meeting. Chapel Hill, NC.

- 3/20/2019 Immunotherapy for Peanut Allergy: Retraining the Allergic Immune System. Durham Technical Community College Spring 2019 Science Seminar Series. Durham, NC.
- 2/25/2019 SLIT: Efficacy and Patient Selection. 2019 American Academy of Allergy, Asthma and Immunology annual scientific meeting. San Francisco, CA.
- 2/23/2019 Tips and Tricks on Teaching a New Generation of Learner. 2019 American Academy of Allergy, Asthma and Immunology annual scientific meeting. San Francisco, CA.
- 11/18/2018 The Pros and Cons of EPIT for Peanut. 2018 American College of Allergy, Asthma and Immunology annual scientific meeting. Seattle, WA.
- 11/3/2018 Food Allergy 101. FARECon featuring Teen Summit 2018. Arlington, VA.
- 10/26/2018 Update on Food Allergy Research. 2018 Children's Mercy Kansas City/ACAAI Conferences On-Line Allergy (COLA) conference series.
- 9/28/2018 Overview and Update on Immunotherapy for Food Allergy. New Jersey Allergy, Asthma and Immunology Society annual meeting. Oyster Bay, NJ.
- 6/23/2018 Overview and Update on Immunotherapy for Food Allergy. Louisiana Society of Allergy, Asthma & Immunology annual meeting. New Orleans, LA.
- 3/11/2018 The Food Allergy Epidemic: Current Landscape and Future Directions. 2018 UNC Kenan-Flagler Business School Wellness Day Keynote Lecture. Chapel Hill, NC.
- 3/10/2018 How clinicians and researchers are collaborating at UNC to develop treatments for debilitating food allergies. 2018 UNC Translational Medicine Symposium. Chapel Hill, NC.
- 3/2/2018 Food Allergy. 2018 American Academy of Allergy, Asthma and Immunology Chrysalis Project Program. Orlando, FL.
- 1/24/2018 Penicillin Allergy. UNC Pediatrics Noon Conference. Chapel Hill, NC.
- 1/19/2018 Basics of Food Allergy. UNC Pediatrics Noon Conference. Chapel Hill, NC.
- 10/1/2017 Overview and Update on Immunotherapy for Food Allergy. Illinois Society of Allergy, Asthma and Immunology annual meeting. Chicago, IL.
- 9/15/2017 Update on Food Allergy Research. 2017 Children's Mercy Kansas City/ACAAI Conferences On-Line Allergy (COLA) conference series.
- 9/12/2017 Innovative Approaches to Food Desensitization. 2017 Current Views in Allergy, Asthma and Immunology (Vol 45) program. Augusta University.

- 8/22/2017 Update on Local Anesthetic Allergy. Division of obstetric anesthesia faculty meeting. Chapel Hill, NC.
- 6/1/2017 Food Allergy Update. 2017 Eastern Allergy Conference. Palm Beach, FL.
- 6/1/2017 Pro/Con Debate: Is oral peanut desensitization ready for mainstream use in clinical practice? 2017 Eastern Allergy Conference. Palm Beach, FL.
- 2/16/2017 Updates on the Diagnosis and Treatment of Food Allergy. Duke Diet and Fitness Center guest lecture series. Durham, NC.
- 2/5/2017 Overview of Angioedema. UNC Internal Medicine noon conference. Chapel Hill, NC.
- 12/1/2016 Historical overview of immunotherapy and the emerging treatment landscape in peanut allergy. Aimmune Investor Research Symposium. New York, NY.
- 8/17/2016 Immunotherapy for the treatment of food allergy. UNC Gillings Department of Nutrition Continuing Education Webinar Series. Chapel Hill, NC.
- 8/17/2016 Pitfalls and pearls in the diagnosis of food allergy. UNC Gillings Department of Nutrition Continuing Education Webinar Series. Chapel Hill, NC.
- 6/16/2015 Overview of drug allergy. UNC Internal Medicine noon conference. Chapel Hill, NC.
- 3/18/2015 Update on angioedema. Charlotte AHEC and UNC SOM 39th annual Internal Medicine Conference, Chapel Hill, NC.
- 3/25/2014 Food allergy: diagnostic and therapeutic challenges. UNC Eschelman School of Pharmacy Noon Lecture Series. Chapel Hill, NC.
- 3/21/2014 Reactions to food: Sorting out allergy from the rest. Charlotte AHEC and UNC SOM 38th annual Internal Medicine Conference, Chapel Hill, NC.
- 1/22/2014 Alternative forms of immunotherapy. Duke Allergy and Immunology Wednesday Seminar Series. Durham, NC.
- 2/22/2013 Difficult Cases: Oral Food Challenges. 2013 American Academy of Allergy, Asthma and Immunology Annual Scientific Meeting. San Antonio, TX.
- 4/4/2012 Chronic urticaria and angioedema. Duke Allergy and Immunology Wednesday Seminar Series, Durham, NC.
- 3/14/2012 Urticaria and angioedema for the internist. Charlotte AHEC and UNC SOM 36th annual Internal Medicine Conference, Chapel Hill, NC.

**Other Lectures**

- 8/24/2021 Update of COVID-19 Vaccine Allergic Reactions. Central Regional Hospital Medical Lecture Series. (virtual)
- 7/6/2021 Approach to Food Allergy. UNC allergy and immunology boot camp lecture series.
- 4/12/2021 AHAA COVID-19 vaccine panel discussion. UNC Asian Health Advocacy Alliance meeting. (virtual)
- 2/20/2021 Hot Topic Discussion Session-Food Allergy. 2021 American Academy of Allergy, Asthma and Immunology Virtual Annual Meeting – Chrysalis Project Program. (virtual)
- 1/12/2021 Review of Allergy Concerns with the COVID-19 Vaccines. Central Regional Hospital Medical Lecture Series. (virtual)
- 12/1/2020 Update on Chronic Idiopathic Urticaria. Central Regional Hospital Medical Lecture Series. (virtual)
- 7/10/2020 Approach to Food Allergy. UNC allergy and immunology boot camp lecture series. (virtual)
- 11/19/2019 Non-IgE mediated Drug Allergies Affecting the Care of Inpatients. Central Regional Hospital Medical Lecture Series. Butner, NC.
- 10/30/2019 Overview of Angioedema. Central Regional Hospital Medical Lecture Series. Butner, NC.
- 7/24/2019 Food Allergy. UNC allergy and immunology boot camp lecture series. Chapel Hill, NC.
- 6/25/2019 Overview of Humoral Immune Deficiency in Adults. Central Regional Hospital Medical Lecture Series. Butner, NC.
- 1/8/2019 Emerging Therapies for Peanut Allergy. Central Regional Hospital Medical Lecture Series. Butner, NC.
- 11/27/2018 Drug Allergies Affecting the Care of Inpatients. Central Regional Hospital Medical Lecture Series. Butner, NC.
- 1/23/2018 Review of Food Allergy and Future Therapies. Central Regional Hospital Medical Lecture Series. Butner, NC.
- 10/17/2017 Overview of Chronic Idiopathic Urticaria. Central Regional Hospital Medical Lecture Series. Butner, NC.

8/23/2017	Pitfalls and Pearls in the Diagnosis and Treatment of Food Allergy. UNC allergy and immunology boot camp lecture series. Chapel Hill, NC.
3/14/2017	I can't stop itching, help! Overview of pruritus. Central Regional Hospital Medical Lecture Series. Butner, NC.
12/6/2016	Overview of angioedema. Central Regional Hospital Medical Lecture Series. Butner, NC.
10/4/2016	An overview of drug allergy. Central Regional Hospital Medical Lecture Series. Butner, NC.
9/19/2016	Hypersensitivity. UNC School of Medicine, TEC foundation phase – immunology block. Chapel Hill, NC.
12/15/2015	Food allergy: diagnosis and innovations in treatment. Central Regional Hospital Medical Lecture Series. Butner, NC.
9/21/2015	Hypersensitivity. UNC School of Medicine, TEC foundation phase – immunology block. Chapel Hill, NC.
8/4/2015	An overview of urticaria and angioedema. Central Regional Hospital Medical Lecture Series. Butner, NC.
7/14/2015	An overview of drug allergy. Central Regional Hospital Medical Lecture Series. Butner, NC.
9/22/2014	Hypersensitivity. UNC School of Medicine, TEC foundation phase – immunology block. Chapel Hill, NC.
7/9/2014	Chronic urticaria and angioedema. UNC allergy and immunology boot camp lecture series. Chapel Hill, NC.
10/17/2012	Update on sublingual immunotherapy for peanut allergy. UNC Allergy and Immunology Seminar Series. Chapel Hill, NC.

## **Research Grants**

### **Active**

- Consortium for Food Allergy Research (CoFAR): OUTMATCH
  - Johns Hopkins University subaward; Project period: 03/01/2019 – 02/29/2024; Principal investigator
- Consortium for Food Allergy Research (CoFAR): OUTMATCH
  - Genentech; Project period: 03/01/2019 – 02/29/2024; Principal investigator
- Consortium for Food Allergy Research (CoFAR): SUNBEAM
  - Johns Hopkins University subaward; Project period: 07/01/2020 – 02/28/2022; Principal investigator
- A double-blind, placebo-controlled, randomized phase III trial to assess the safety and efficacy of

- Viaskin® Peanut in peanut-allergic young children 1-3 years of age (EPITOPE study)
  - DBV Technologies; Project period: 3/28/2017 – 3/27/2022; Principal investigator
- Open-label extension study to evaluate the long-term clinical benefit and safety of DBV712 in peanut-allergic children (EPOPEX study)
  - DBV Technologies; Project period: 11/2/2018 – 9/30/2025; Principal investigator
- Peanut oral immunotherapy study of early intervention for desensitization (ARC005 study)
  - Aimmune Therapeutics; Project period: 9/27/2018 – 8/31/2025; Principal investigator
- A multi-center, open-label, long-term safety study of AR101 characterized oral desensitization immunotherapy in subjects who participated in a prior AR101 study (ARC008 study)
  - Aimmune Therapeutics; Project period: 9/8/2017 – 9/8/2020; Principal investigator
- A phase 2, multi-center, randomized, double-blind, placebo-controlled study in pediatric subjects with peanut allergy to evaluate the efficacy and safety of Dupilumab and adjunct to peanut oral immunotherapy (R668-ALG-16114 study)
  - Regeneron Pharmaceuticals; Project period: 5/10/2019 – 5/9/2024; Principal investigator

### **Completed**

- A Double-blind, Placebo-controlled, Randomized Phase 3 Pivotal Trial to Assess the Efficacy and Safety of Peanut Epicutaneous Immunotherapy With Viaskin Peanut in Peanut-allergic Children (PEPITES study)
  - DBV Technologies; Project period: 3/2/2016 – 12/31/2019; Principal investigator
- Open-label follow-up study of the PEPITES study to evaluate the long-term efficacy and safety of Viaskin® peanut (PEOPLE study)
  - DBV Technologies; Project period: 5/9/2017 – 5/8/2022; Principal investigator
- Long-term assessment of safety and therapeutic benefit of Viaskin® Peanut epicutaneous treatment in peanut-allergic children: A 6 month randomization, double-blind, placebo-controlled phase III study followed by an open label active treatment (REALISE study)
  - DBV Technologies; Project period: 1/6/2017 – 12/31/2020; Principal investigator
- Peanut allergy oral immunotherapy study of AR101 for desensitization in children and adults (PALISADE study)
  - Aimmune Therapeutics; Project period: 3/1/2016 – 2/28/2018; Principal investigator
- Peanut allergy oral immunotherapy study of AR101 for desensitization in children and adults (PALISADE) follow-on study (ARC004 study)
  - Aimmune Therapeutics; Project period: 3/21/2017 – 5/31/2022; Principal investigator
- Real-world AR101 market-supporting experience study in peanut-allergic children ages 4 to 17 years (ARC007 RAMSES study)
  - Aimmune Therapeutics; Project period: 5/25/2017 – 6/28/2021; Principal investigator
- Real-world AR101 market-supporting experience study in peanut-allergic children, active treatment arm open-label extension study (ARC011 RAMSES OLE study)
  - Aimmune Therapeutics; Project period: 11/17/2017 – 12/1/2022; Principal investigator
- A phase 2, double-blind, placebo-controlled, parallel group, multiple dose study to investigate Etokimab (ANB020) in adult subjects with chronic rhinosinusitis with nasal polyposis (ANB020-006 study)
  - AnaptysBio; Project period: 3/19/2019 – 3/31/2021; Principal investigator
- A randomized, double-blind, placebo-controlled, multi-centre study to assess the safety, tolerability and pharmacodynamics of HAL-MPE1 subcutaneous immunotherapy in adult and pediatric subjects with peanut allergy

- HAL Allergy, Project period: 1/1/2017 – 12/31/2019; Principal investigator
- A Phase 1, Randomized, Placebo Controlled study to Evaluate Safety, Tolerability and Immune Response in Adults Allergic to Peanut after Receiving Intradermal or Intramuscular Administration of ASP0892 (ARA LAMP vax), a single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine
  - Astellas Pharma Global Development, Project period: 11/23/2016 – 11/22/2018; Principal investigator

## **Clinical Trials**

### **Active**

- Consortium for Food Allergy Research (CoFAR): OUTMATCH
  - Johns Hopkins University subaward; Project period: 03/01/2019 – 02/29/2024; Principal investigator
- Consortium for Food Allergy Research (CoFAR): OUTMATCH
  - Genentech; Project period: 03/01/2019 – 02/29/2024; Principal investigator
- Consortium for Food Allergy Research (CoFAR): SUNBEAM
  - Johns Hopkins University subaward; Project period: 07/01/2020 – 02/28/2022; Principal investigator
- A double-blind, placebo-controlled, randomized phase III trial to assess the safety and efficacy of Viaskin® Peanut in peanut-allergic young children 1-3 years of age (EPITOPE study)
  - DBV Technologies; Project period: 3/28/2017 – 3/27/2022; Principal investigator
- Open-label extension study to evaluate the long-term clinical benefit and safety of DBV712 in peanut-allergic children (EPOPEX study)
  - DBV Technologies; Project period: 11/2/2018 – 9/30/2025; Principal investigator
- Peanut oral immunotherapy study of early intervention for desensitization (ARC005 study)
  - Aimmune Therapeutics; Project period: 9/27/2018 – 8/31/2025; Principal investigator
- A multi-center, open-label, long-term safety study of AR101 characterized oral desensitization immunotherapy in subjects who participated in a prior AR101 study (ARC008 study)
  - Aimmune Therapeutics; Project period: 9/8/2017 – 9/8/2020; Principal investigator
- A phase 2, multi-center, randomized, double-blind, placebo-controlled study in pediatric subjects with peanut allergy to evaluate the efficacy and safety of Dupilumab and adjunct to peanut oral immunotherapy (R668-ALG-16114 study)
  - Regeneron Pharmaceuticals; Project period: 5/10/2019 – 5/9/2024; Principal investigator

### **Completed**

- A Double-blind, Placebo-controlled, Randomized Phase 3 Pivotal Trial to Assess the Efficacy and Safety of Peanut Epicutaneous Immunotherapy With Viaskin Peanut in Peanut-allergic Children (PEPITES study)
  - DBV Technologies; Project period: 3/2/2016 – 12/31/2019; Principal investigator
- Open-label follow-up study of the PEPITES study to evaluate the long-term efficacy and safety of Viaskin® peanut (PEOPLE study)
  - DBV Technologies; Project period: 5/9/2017 – 5/8/2022; Principal investigator
- Long-term assessment of safety and therapeutic benefit of Viaskin® Peanut epicutaneous treatment in peanut-allergic children: A 6 month randomization, double-blind, placebo-controlled phase III study followed by an open label active treatment (REALISE study)
  - DBV Technologies; Project period: 1/6/2017 – 12/31/2020; Principal investigator

- Peanut allergy oral immunotherapy study of AR101 for desensitization in children and adults (PALISADE study)
  - Aimmune Therapeutics; Project period: 3/1/2016 – 2/28/2018; Principal investigator
- Peanut allergy oral immunotherapy study of AR101 for desensitization in children and adults (PALISADE) follow-on study (ARC004 study)
  - Aimmune Therapeutics; Project period: 3/21/2017 – 5/31/2022; Principal investigator
- Real-world AR101 market-supporting experience study in peanut-allergic children ages 4 to 17 years (ARC007 RAMSES study)
  - Aimmune Therapeutics; Project period: 5/25/2017 – 6/28/2021; Principal investigator
- Real-world AR101 market-supporting experience study in peanut-allergic children, active treatment arm open-label extension study (ARC011 RAMSES OLE study)
  - Aimmune Therapeutics; Project period: 11/17/2017 – 12/1/2022; Principal investigator
- A phase 2, double-blind, placebo-controlled, parallel group, multiple dose study to investigate Etokimab (ANB020) in adult subjects with chronic rhinosinusitis with nasal polyposis (ANB020-006 study)
  - AnaptysBio; Project period: 3/19/2019 – 3/31/2021; Principal investigator
- A randomized, double-blind, placebo-controlled, multi-centre study to assess the safety, tolerability and pharmacodynamics of HAL-MPE1 subcutaneous immunotherapy in adult and pediatric subjects with peanut allergy
  - HAL Allergy, Project period: 1/1/2017 – 12/31/2019; Principal investigator
- A Phase 1, Randomized, Placebo Controlled study to Evaluate Safety, Tolerability and Immune Response in Adults Allergic to Peanut after Receiving Intradermal or Intramuscular Administration of ASP0892 (ARA LAMP vax), a single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine
  - Astellas Pharma Global Development, Project period: 11/23/2016 – 11/22/2018; Principal investigator

## **Professional Service**

### ***Service to Discipline Memberships/Committees***

2/2021 – present	Vice chair, AAAAI Clinical Rotation Committee
2/2021 – present	Vice chair, AAAAI CME/MOC Committee
2/2021 – present	Member, AAAAI Office of Medical Education
11/2020 – present	Member, Society for Pediatric Research
10/2019 – present	Member, US FDA Pulmonary-Allergy Drugs Advisory Committee
2/2019 – present	Ad-hoc DSMB member, National Institute of Allergy and Infectious Diseases
3/2018 – present	Member, World Allergy Organization (WAO) WinAIT committee
9/2012 – present	Member, AAAAI Food allergy, Anaphylaxis, Dermatology and Drug allergy Interest Group
7/2011 – present	Fellow of American Academy of Allergy, Asthma, and Immunology (AAAAI)
7/2011 – present	Fellow of American College of Allergy, Asthma, and Immunology (ACAAI)
2/2019 – 2/2021	Executive committee: pediatric counselor, AAAAI Program Directors Assembly
5/2017 – 2/2021	Member, AAAAI Clinical Rotation Committee
4/2016 – 2/2021	Member, AAAAI CME/MOC Committee
3/2014 – 4/2016	Member, AAAAI Needs Assessment and Outcomes Committee

### ***Manuscript Review***

Section editor: Current Allergy and Asthma Reports  
Ad hoc reviewer (>40 reviewed): Journal of Allergy and Clinical Immunology In Practice  
Ad hoc reviewer (1-5 reviewed): Journal of Allergy and Clinical Immunology, Annals of Asthma, Allergy and Immunology, Allergy, BMJ Open, International Archives of Allergy and Immunology, The Lancet Child and Adolescent Health, Pediatric Allergy and Immunology, Immunology, Case Reports in Pediatrics, Expert Review of Clinical Immunology, PLOS ONE

***Service to University***

9/2020 UNC SOM ad-hoc 5-year center review committee  
4/2018 – 6/2021 Medical Director Member, Department of Medicine Outpatient Leaders Group  
6/2016 – present Physician Champion – UNC Grateful Patient Program  
1/2014 – 6/2021 Member, Thurston Arthritis Research Center and Division of Rheumatology, Allergy & Immunology 5-year Strategic Plan – Education Committee  
6/2015 – 12/2015 Member, Carolina Value – School of Medicine Technology Transfer  
9/2014 – 2/2015 Implementation Team Member, Academy of Educators – School of Medicine EPIC Utilization Committee  
3/2014 – 4/2014 Superuser, Epic@UNC Project  
8/2013 – 4/2014 Subject Matter Expert, Adult and Pediatric Allergy, Epic@UNC Project  
7/2013 – 2/2014 Member, UNC – Streamlining the Referral Process Task Force  
7/2013 – 2/2014 Member, UNC – Provider Review of Referrals Task Force

